Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short-term Investments: 2020-2023

Historic Short-term Investments for BridgeBio Pharma (BBIO) over the last 4 years, with Dec 2023 value amounting to $58.9 million.

  • BridgeBio Pharma's Short-term Investments fell 97.85% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 97.85%. This contributed to the annual value of $58.9 million for FY2023, which is 55.42% up from last year.
  • As of FY2023, BridgeBio Pharma's Short-term Investments stood at $58.9 million, which was up 55.42% from $37.9 million recorded in FY2022.
  • In the past 5 years, BridgeBio Pharma's Short-term Investments registered a high of $58.9 million during FY2023, and its lowest value of $139,000 during FY2020.
  • Over the past 3 years, BridgeBio Pharma's median Short-term Investments value was $37.9 million (recorded in 2022), while the average stood at $32.4 million.
  • Data for BridgeBio Pharma's Short-term Investments shows a peak YoY skyrocketed of 21,329.38% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows BridgeBio Pharma's Short-term Investments stood at $139,000 in 2020, then increased by 27.34% to $177,000 in 2021, then surged by 21,329.38% to $37.9 million in 2022, then skyrocketed by 55.42% to $58.9 million in 2023.